CG
MRNA icon

Caprock Group’s Moderna MRNA Stock Holding History

Caprock Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$544K Sell
7,765
-1,181
-13% -$61.1K 0.01% 825
2026
Q1 		$454K Buy
+8,946
New +$417K 0.01% 780
2025
Q4 		– Sell
-13,884
Closed -$334K – 1265
2025
Q3 		$334K Buy
+13,884
New +$387K 0.01% 914
2025
Q1 		– Sell
-4,886
Closed -$203K – 1143
2024
Q4 		$203K Buy
+4,886
New +$234K 0.01% 935
2024
Q3 		– Sell
-5,122
Closed -$608K – 951
2024
Q2 		$608K Buy
5,122
+2,040
+66% +$258K 0.02% 489
2024
Q1 		$328K Buy
3,082
+621
+25% +$62.6K 0.02% 527
2023
Q4 		$245K Sell
2,461
-42
-2% -$3.53K 0.02% 593
2023
Q3 		$258K Buy
+2,503
New +$279K 0.02% 538

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Caprock Group's MRNA Position: Q2 2026 in Review

Caprock Group reduced its Moderna (MRNA) stake by 13% in Q2 2026, selling an estimated $61.1K and leaving 7,765 shares worth $544K. The position accounts for 0.01% of the portfolio, ranked #825.

Caprock Group first reported a position in MRNA in Q3 2023 and has held it in 8 quarters since. The position peaked at $608K in Q2 2024. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Caprock Group held 7,765 shares of Moderna worth $544K as of Q2 2026.
  • Caprock Group sold 1,181 Moderna shares in Q2 2026, an estimated $61.1K.
  • Moderna made up 0.01% of Caprock Group's portfolio in Q2 2026, its #825 holding.
  • Caprock Group first reported a position in Moderna in Q3 2023 and has held it in 8 quarters since.
  • Caprock Group's Moderna position peaked at $608K in Q2 2024.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.